Janux Therapeutics
Agnes Zong is a Senior Scientist at Janux Therapeutics since January 2024, with prior experience as a Scientist at Turnstone Biologics and Fate Therapeutics Inc., and as a Graduate Research Assistant at Indiana University Bloomington. Zong has extensive expertise in identifying cancer stem cell populations through flow cytometry, proficient in gene editing with the CRISPR/Cas9 system, and lentiviral transduction. Zong's earlier roles include a translational research internship at AbbVie and undergraduate research at China Medical University, focusing on microRNA-100's role in breast cancer and developing drug delivery systems. Agnes Zong holds a PhD in Pharmacology from Indiana University Bloomington and a BS in Clinical Pharmacy from China Medical University.
This person is not in the org chart
Janux Therapeutics
1 followers
Janux Therapeutics is developing safe, effective novel immunotherapies with the company’s proprietary TRACTr technology. Janux’s TRACTr technology employs a modular design to rapidly engineer drug candidates against specific targets.